01 — At A Glance
They Admit It. They Destroyed Revenue On Purpose.
- 52-Week High / Low₹409 / ₹268
- Q3 FY26 Revenue₹231 Cr
- Q3 FY26 PAT₹12.4 Cr
- Q3 EPS₹1.24
- Full-Year FY25 EPS₹6.95
- Book Value₹62.9
- Price to Book4.68x
- Dividend Yield0.03%
- Debt / Equity0.58x
- ROCE13.2%
The Admission Nobody Wanted: In Q3 FY26, Gufic’s management explicitly told investors they sacrificed ₹14–16 crore of revenue to fix working-capital chaos. PAT crashed 36% YoY as a result. But here’s the plot twist: management said this during the earnings call on February 16, 2026 — AFTER the Q3 results were published and the stock had already crashed 16% in 3 months. Translation: bad communication mixed with worse execution.
02 — Introduction
When Your Pharma Shop Gets Too Successful For Hospital Billing
Gufic BioSciences is a mid-sized pharmaceutical company that manufactures injectables, APIs (bulk drugs), botulinum toxin for aesthetics, and contract manufacturing for other pharma companies. It’s been around since the 1960s—five decades of boring, reliable manufacturing. Until December 2024, when they opened a ₹300+ crore Indore manufacturing plant and suddenly things got complicated.
The company makes products that hospitals actually buy repeatedly: sepsis treatments, resistant infection antibiotics, fertility hormones, and now (beginning 2026) a botulinum toxin business with 23% market share and a freshly-signed Canadian fillers licensing deal. Repeat customers. Long qualification cycles. The boring foundation that actually makes money — except when it doesn’t.
In Q3 (October-December 2025), management did something unusual: it admitted that it had deliberately switched from direct-to-hospital billing (good for reported revenue, terrible for cash collection) back to distributor/stockist billing (slower revenue reported, faster cash in). This caused a ₹14–16 crore revenue “hit” that management only explained to investors during the February 2026 earnings call. By then, the stock had already tanked. The lesson: admit your mistakes, but admit them BEFORE quarterly results, not after.
From The Feb 16 Concall: CFO: “We are revamping our operations from going from direct hospital supply to taking it back as a stockist because a lot of our working capital was getting affected in the long cycle.” CEO added: “I don’t want to have one more year where I submit something and I don’t deliver.” Translation: Panic mixed with occasional competence.
03 — Business Model: The Injection, Toxin, And Bulk Drug Tango
Four Businesses. One Balance Sheet. All Of Them Complicated.
Members get full access to every article.
